Stock Analysis Report

Executive Summary

Coloplast A/S develops and markets intimate healthcare products and services worldwide.



Established dividend payer with adequate balance sheet.

Similar Companies

Share Price & News

How has Coloplast's share price performed over time and what events caused price changes?

Latest Share Price and Events

Market Performance

7 Day Return




US Medical Equipment


US Market

1 Year Return




US Medical Equipment


US Market

Return vs Industry: CLPB.F exceeded the US Medical Equipment industry which returned 10.1% over the past year.

Return vs Market: CLPB.F exceeded the US Market which returned 5.6% over the past year.

Shareholder returns

7 Day2.8%1.7%2.3%
30 Day2.7%-1.7%-1.0%
90 Day1.5%-1.7%-0.7%
1 Year22.8%22.8%11.0%10.1%7.9%5.6%
3 Year69.0%69.0%70.4%65.2%45.6%36.3%
5 Year51.9%51.9%128.5%103.2%65.8%47.6%

Price Volatility Vs. Market

How volatile is Coloplast's share price compared to the market and industry in the last 5 years?

Simply Wall St News

No news available


Is Coloplast undervalued compared to its fair value and its price relative to the market?


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Undervalued: CLPB.F ($120) is trading above our estimate of fair value ($75.72)

Significantly Undervalued: CLPB.F is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: CLPB.F is poor value based on its PE Ratio (41.3x) compared to the Medical Equipment industry average (41.1x).

PE vs Market: CLPB.F is poor value based on its PE Ratio (41.3x) compared to the US market (17.7x).

Price to Earnings Growth Ratio

Low PEG Ratio: CLPB.F is poor value based on its PEG Ratio (5x)

Price to Book Ratio

PB vs Industry: CLPB.F is overvalued based on its PB Ratio (28.6x) compared to the US Medical Equipment industry average (3.7x).

Next Steps

  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Coloplast forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLPB.F's forecast earnings growth (8.3% per year) is above the savings rate (2.7%).

Earnings vs Market: CLPB.F's earnings (8.3% per year) are forecast to grow slower than the US market (14.5% per year).

High Growth Earnings: CLPB.F's earnings are forecast to grow, but not significantly.

Revenue vs Market: CLPB.F's revenue (7.7% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: CLPB.F's revenue (7.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

High Future ROE: CLPB.F's Return on Equity is forecast to be very high in 3 years time (63%).

Next Steps

Past Performance

How has Coloplast performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Past Earnings Growth Analysis

Earnings Trend: CLPB.F's earnings have grown by 16.1% per year over the past 5 years.

Accelerating Growth: CLPB.F's earnings growth over the past year (7.9%) is below its 5-year average (16.1% per year).

Earnings vs Industry: CLPB.F earnings growth over the past year (7.9%) underperformed the Medical Equipment industry 28.2%.

Return on Equity

High ROE: CLPB.F's Return on Equity (69.4%) is considered outstanding.

Return on Assets

ROA vs Industry: CLPB.F has a higher Return on Assets than the Medical Equipment industry average last year.

Return on Capital Employed

ROCE Improving: CLPB.F's Return on Capital Employed has declined over the past 3 years.

Next Steps

Financial Health

How is Coloplast's financial position?

Financial Position Analysis

Short Term Liabilities: CLPB.F's short term assets (DKK6.4B) exceeds its short term liabilities (DKK6.0B)

Long Term Liabilities: CLPB.F's short term assets (6.4B) exceeds its long term liabilities (657.0M)

Debt to Equity History and Analysis

Debt Level: CLPB.F's debt to equity ratio (47.8%) is considered high

Reducing Debt: CLPB.F's debt to equity ratio has increased from 2.8% to 47.8% over the past 5 years.

Debt Coverage: CLPB.F's debt is well covered by operating cash flow (146.5%).

Interest Coverage: CLPB.F earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Inventory Level: CLPB.F has a high level of physical assets or inventory.

Debt Coverage by Assets: CLPB.F's debt is covered by short term assets (assets are 2.258800x debt).

Next Steps


What is Coloplast's current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market


Current dividend yield vs market & industry

Stability and Growth of Payments

Notable Dividend: CLPB.F's dividend (2%) is higher than the bottom 25% of dividend payers in the US market (1.46%).

High Dividend: CLPB.F's dividend (2%) is low compared to the top 25% of dividend payers in the US market (3.76%).

Stable Dividend: CLPB.F's dividends per share have been stable in the past 10 years.

Growing Dividend: CLPB.F's dividend payments have increased over the past 10 years.

Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (56.7%), CLPB.F's dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: CLPB.F's dividends in 3 years are forecast to be covered by earnings (83.2% payout ratio).

Next Steps


What is the CEO of Coloplast's salary, the management and board of directors tenure and is there insider trading?


Average management tenure


Kristian Villumsen (49yo)





Mr. Kristian Villumsen has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an Executive Vice President of Chronic Care at Coloplast A/S since July  ...

CEO Compensation Analysis

Compensation vs. Market: Kristian has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Kristian's compensation has been consistent with company performance over the past year.

Management Age and Tenure


Average Tenure


Average Age

Experienced Management: CLPB.F's management team is seasoned and experienced (5.3 years average tenure).

Board Age and Tenure


Average Tenure


Average Age

Experienced Board: CLPB.F's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Management Team

  • Allan Rasmussen (52yo)

    Executive Vice President of Global Operations

    • Tenure: 5.3yrs
    • Compensation: ø8.40m
  • Nicolai Andersen

    Senior Vice President of Wound Care

    • Tenure: 0yrs
  • Kristian Villumsen (49yo)

    President & CEO

    • Tenure: 0.8yrs
    • Compensation: ø10.40m
  • Anders Lonning-Skovgaard (47yo)

    Executive VP & CFO

    • Tenure: 5.3yrs
    • Compensation: ø8.60m
  • Alain Morvan

    Senior Vice President of Sales Europe

    • Tenure: 7.5yrs
  • Oliver Johansen (48yo)

    Senior Vice President of Global R&D

    • Tenure: 6.8yrs
  • Paul Marcun

    Executive Vice President of Chronic Care

    • Tenure: 0yrs
  • Ellen Bjurgert

    Vice President of Investor Relations

    • Tenure: 3yrs
  • Manu Varma

    Senior Vice President of Chronic Care - North America

    • Tenure: 1.5yrs
  • Lina Danstrup

    Senior Media Relations Manager of Corporate Communications

    • Tenure: 0yrs

Board Members

  • Carsten Hellmann (55yo)

    Independent Director

    • Tenure: 1.8yrs
  • Jørgen Tang-Jensen (63yo)

    Independent Director

    • Tenure: 11.8yrs
  • Lars Rasmussen (60yo)

    Chairman of the Board

    • Tenure: 0.8yrs
    • Compensation: ø19.80m
  • Niels Louis-Hansen (72yo)

    Deputy Chairman

    • Tenure: 0yrs
    • Compensation: ø1.00m
  • Thomas Barfod (49yo)

    Senior Controller & Director

    • Tenure: 12.8yrs
  • Jette Nygaard-Andersen (51yo)

    Independent Director

    • Tenure: 3.8yrs
  • Birgitte Nielsen (56yo)

    Independent Director

    • Tenure: 3.8yrs
  • Nikolaj Gundersen (50yo)


    • Tenure: 1.8yrs
  • Roland Pedersen (57yo)


    • Tenure: 1.8yrs

Company Information

Coloplast A/S's company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Coloplast A/S
  • Ticker: CLPB.F
  • Exchange: OTCPK
  • Founded: 1954
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: ø170.079b
  • Listing Market Cap: ø25.321b
  • Shares outstanding: 212.17m
  • Website: https://www.coloplast.com

Number of Employees


  • Coloplast A/S
  • Holtedam 1-3
  • Humlebæk
  • 3050
  • Denmark


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLPB.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDMar 1993
COLO BCPSE (OMX Nordic Exchange Copenhagen)YesClass B SharesDKDKKMar 1993
CBHDDB (Deutsche Boerse AG)YesClass B SharesDEEURMar 1993
COLOBCBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBDKKMar 1993
0QBOLSE (London Stock Exchange)YesClass B SharesGBDKKMar 1993
COLOBSWX (SIX Swiss Exchange)YesClass B SharesCHCHFMar 1993
COLOWBAG (Wiener Boerse AG)YesClass B SharesATEURMar 1993
0QBO NBMV (Bolsa Mexicana de Valores)YesClass B SharesMXMXNMar 1993


Coloplast A/S develops and markets intimate healthcare products and services worldwide. The company operates through three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ...

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 23:54
End of Day Share Price2019/10/15 00:00
Annual Earnings2018/09/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.